Notably, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are endorsed as adjuncts to maximally tolerated statin therapy for patients with CKD and familial hypercholesterolemia or clinical ASCVD who do not achieve LDL-C targets [9]. Here, PCSK9 is linked to atherosclerosis.